European Commission Approves Bavencio as First Immunotherapy for Adult Metastatic Merkel Cell Carcinoma – Immuno-Oncology News
Immuno-Oncology News |
European Commission Approves Bavencio as First Immunotherapy for Adult Metastatic Merkel Cell Carcinoma
Immuno-Oncology News The European Commission (EC) has granted Bavencio (avelumab) marketing approval as the first immunotherapy to treat the aggressive skin cancer metastatic Merkel cell carcinoma in adults. The decision will allow an introduction of Bavencio — developed … Pfizer-Merck KGaA Skin Cancer Drug Bavencio Gets EU Approval Merck, Pfizer get EC approval for skin cancer drug Bavencio |
